- Dividend Brief
- Posts
- The Pharma Giant That Refuses to Slow Down
The Pharma Giant That Refuses to Slow Down
A pharmaceutical powerhouse is making headlines with a blockbuster acquisition while quietly delivering double-digit revenue growth. Its cash-generating machine keeps humming, and income investors are collecting a yield backed by more than half a century of unbroken raises. Here's why this Dividend King deserves a closer look.
Most $10 billion acquisitions send investors running for the exits. Not this time. When this name dropped nearly $11 billion on a biotech deal last month, the stock barely flinched.
Why? Because the revenue engine underneath it is humming louder than it has in years, the dividend just keeps climbing, and the pipeline refresh is solving the one problem bears have been harping on for three years straight.
This is a Dividend King with teeth. And the setup heading into Q2 earnings is better than the Street thinks.
Growth Watch (Sponsored)
After analyzing thousands of companies, our analysts pinpointed the 5 Stocks Set to Double based on accelerating performance, improving fundamentals, and strong technical signals.
This newly released report explains why these five could be positioned for major moves in the year ahead.
While results aren’t guaranteed, previous reports uncovered gains as high as +175%, +498%, and +673%.
Access the free report before midnight.
See the 5 Stocks Set to Double.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
Meet the Pick
The stock is AbbVie Inc. (NYSE: ABBV). Global biopharmaceutical giant. Immunology, oncology, neuroscience, aesthetics. Market cap sits around $450 billion, shares near $254 after a 35% run over the past twelve months.
So what makes AbbVie different from the rest of the pharma crowd? Two things.
First, it's one of the true Dividend Kings, with 52 consecutive years of annual increases, a streak inherited from parent Abbott Laboratories and extended without interruption since the 2013 spinoff. Second, it's pulled off the rarest trick in pharma: replacing a $20 billion drug (Humira) with two successors that are actually growing faster than what they replaced.
Building a Biotech Empire, One Deal at a Time
AbbVie's playbook has always been straightforward: develop blockbuster drugs, generate enormous cash flows, and reinvest in the next generation of therapies. The company announced a $10.9 billion acquisition of Apogee Therapeutics on June 22, adding next-generation immunology candidates to a pipeline that's already firing on all cylinders.
Apogee's APG808, a long-acting anti-IL-13 antibody targeting atopic dermatitis, is designed to challenge Sanofi's juggernaut Dupixent. The deal also brings APG273, a combination antibody targeting IL-13 and TSLP for asthma.
Gold Protection Play (Sponsored)
Tensions in Iran are escalating, not cooling down.
Airstrikes continue, oil routes are under pressure, and analysts warn the economic fallout could deepen.
Gas prices are already climbing.
Inflation could spike again.
And portfolios heavy in stocks and bonds may be exposed if this situation worsens.
That's why many Americans are moving a portion of their retirement savings into physical gold — an asset that historically holds value during periods of conflict and uncertainty.
Red State Gold Group's FREE Gold IRA Guide shows how eligible IRA or 401(k) funds can be rolled into physical gold and silver.
Get your free guide today
Two things are really live in the business model right now:
- Skyrizi and Rinvoq are compounding at 20%+ combined growth, now approaching $32 billion in 2026 guidance.
- The Apogee deal extends the immunology franchise runway well into the 2030s, buying time before the next patent cliff hits.
For AbbVie, this is a calculated expansion of its strongest franchise at a time when it has the revenue base and free cash flow to absorb the cost. And the Street isn't modeling the full pipeline optionality yet.
AI Auto Play (Sponsored)
Marc Chaikin’s system once flashed bearish on a little-known auto tech stock before it fell 35%.
Now that same system has flipped to “Very Bullish” after the company landed a major Nvidia-linked partnership tied to the future of self-driving cars.
Chaikin says this could be a better way to play the autonomous vehicle boom than Tesla.
See the ticker Chaikin is watching now.
Revenue Beats and Raised Guidance
AbbVie's Q1 2026 earnings tell the story of a company accelerating into its next chapter. Total net revenue hit $15.0 billion, up 12.4% year over year, beating internal forecasts by $300 million.
Adjusted earnings per share came in at $2.65, up from $2.46 a year ago. Management responded by raising full-year adjusted EPS guidance to $14.08-$14.28, reflecting confidence that the growth trajectory has staying power.
The math is simple. Every quarter Skyrizi and Rinvoq add to the top line, the Humira drag matters less. Immunology is already the majority of revenue, and it's growing at double digits. Operating margins are expanding as the portfolio mix shifts toward higher-margin biologics.
Action: Accumulate shares in the $240 to $260 zone. The setup is a double-digit growth pharma trading at a reasonable multiple with a Dividend King yield as your floor. |
Which dividend metric do you prioritize most when screening for income stocks? |
Skyrizi and Rinvoq: The Twin Engines
The Humira chapter may be closing, but AbbVie's next act is already outpacing it. Skyrizi, the IL-23 inhibitor treating psoriasis and inflammatory bowel disease, delivered $4.5 billion in Q1 alone, up 29.2% operationally. Rinvoq, a JAK inhibitor spanning rheumatology and gastroenterology, posted $2.119 billion in Q1 revenue, growing 23.3%.
Together, the immunology franchise hit $7.3 billion for the quarter. Management raised 2026 guidance to $21.6 billion for Skyrizi and $10.2 billion for Rinvoq, with combined growth of more than 20% for the year.
This is the piece that gets re-rated as analysts model the next three years. Humira peaked at $21 billion. Skyrizi alone is on pace to surpass that.
The Numbers Behind the Momentum
The financial engine is broad-based. AbbVie's neuroscience franchise is guided for $12.6 billion in 2026, while aesthetics continues to add incremental revenue.
The company generated $10.3 billion in free cash flow over the trailing twelve months, providing ample coverage for dividends, debt reduction, and acquisitions.
A few things to anchor on:
- Revenue growth has been positive every quarter since the Humira patent cliff bottomed out, even through biosimilar headwinds.
- The Apogee deal will be funded with debt rather than cash reserves, leaving AbbVie's liquidity intact.
- Free cash flow conversion remains strong, supporting the dividend, buybacks, and continued M&A.
- Analysts maintain a consensus price target of roughly $267, with the most bullish call from BMO Capital at $300.
The just-raised guidance confirms management sees the revenue trajectory as durable. Companies don't lift EPS guidance two quarters in a row if there's doubt about what's coming. That's the tell.
Action: At a 2.7% yield with 6-7% annual growth, ABBV offers income investors a rare combination of current yield and dividend growth. |
A Dividend Crown 52 Years in the Making
AbbVie pays a quarterly dividend of $1.73 per share, which is that's $6.92 annually for a yield of approximately 2.7%. More impressive is the pedigree: AbbVie has raised its dividend every single year for 52 consecutive years.
The payout ratio sits near 40% of free cash flow, well within sustainable territory. The 5-year dividend growth CAGR is 6.8%, meaning income investors are compounding income gains.
What Could Go Wrong
No Dividend King is bulletproof. A few things could push AbbVie sideways before the thesis plays out:
- AbbVie carries $69 billion in total debt against negative shareholder equity of $3.2 billion, which is a legacy of the Allergan mega-merger.
- Humira continues to erode, declining 40% operationally in Q1 as biosimilar competition intensifies.
- The IRA's Part D drug pricing negotiations could pressure margins on Skyrizi or Rinvoq down the road.
- The Apogee acquisition adds integration risk and near-term leverage at a time when the balance sheet already runs hot.
- The stock trades at roughly 18x forward earnings, which isn't cheap by pharma standards.
Debt is the one I'd watch most. While free cash flow comfortably covers obligations, rising rates increase refinancing costs. Investors should monitor the debt reduction pace alongside pipeline execution.
Putting It All Together
If you're building long-haul income and you want a business that's proven it can grow the payout through patent cliffs, acquisitions, and market chaos, AbbVie fits the bill.
The Apogee deal confirms what the revenue numbers have been telling you all year, and management has visibility into durable growth; the Skyrizi and Rinvoq ramp is working, and the immunology franchise has runway into the 2030s.
You're not buying this for fireworks. You're buying it for the math. A 2.7% starting yield, mid-to-high single-digit dividend growth, and a pharmaceutical franchise that just proved it can replace the biggest drug in history and come out stronger. Accumulate in the $240 to $260 zone, reinvest the dividends, and let it work.
Action Recap
✅ Buy Zone: $240 to $260
✅ Catalysts to Watch: Q2 earnings (July 31) for confirmation of Skyrizi/Rinvoq momentum, Apogee deal close expected Q3 2026, potential new indication approvals
✅ Medium-Term Target: $285 to $300 over the next 12 to 18 months as pipeline optionality gets priced in
✅ Risk Management Tip: Reassess if shares break below $220 or if Skyrizi growth decelerates below 15% for two consecutive quarters
Setup Scorecard
Entry Zone: $240 to $260
Target: $285 to $300 over 12 to 18 months
Stop Loss: Reassess below $220
Catalyst Timeline: Q2 earnings July 31, Apogee deal close Q3 2026, potential Rinvoq label expansions H2 2026
Confidence Level: Medium-High. The franchise transition is working, the dividend signal is strong, but debt levels and IRA pricing risk require patience and the thesis plays out over quarters, not weeks.
That’s all for today’s edition of the Dividend Brief.
Thanks for reading, and if you have any feedback or dividend stocks you want me to take a look at, just reply to this email!
—Noah Zelvis
DividendBrief.com